Evidence map›Paper›PMID 25520915›Full record

ArticleBioMedicine2014

Evolving Personalized Therapy for Castration-Resistant Prostate Cancer.

Hsin-Ho Liu, Yuh-Shyan Tsai, Chen-Li Lai, Chih-Hsin Tang, Chih-Ho Lai, Hsi-Chin Wu, Jer-Tsong Hsieh, Che-Rei Yang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BioMedicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Observational
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hsin-Ho LiuDepartment of Urology, University of Texas Southwestern Medical Center, Dallas, Texas, USA ; Division of Urology, Department of Surgery, Taichung Tzu Chi General Hospital, Taichung, Taiwan ; Department of Bio-Industrial Mechatronics Engineering, National Taiwan University, Taipei, Taiwan.
Yuh-Shyan TsaiDepartment of Urology, University of Texas Southwestern Medical Center, Dallas, Texas, USA ; Department of Urology, Medical College and Hospital, National Cheng Kung University, Tainan, Taiwan.
Chen-Li LaiDepartment of Urology, University of Texas Southwestern Medical Center, Dallas, Texas, USA ; Department of Urology, Medical College and Hospital, National Cheng Kung University, Tainan, Taiwan.
Chih-Hsin TangSchool of Medicine, China Medical University, Tainan, Taiwan.
Chih-Ho LaiDepartment of Urology, University of Texas Southwestern Medical Center, Dallas, Texas, USA ; School of Medicine, China Medical University, Tainan, Taiwan.
Hsi-Chin WuSchool of Medicine, China Medical University, Tainan, Taiwan ; Department of Urology, China Medical University Hospital, Tainan, Taiwan.
Jer-Tsong HsiehDepartment of Urology, University of Texas Southwestern Medical Center, Dallas, Texas, USA ; Graduate Institute of Cancer Biology, China Medical University, Tainan, Taiwan.
Che-Rei YangSchool of Medicine, China Medical University, Tainan, Taiwan ; Department of Urology, China Medical University Hospital, Tainan, Taiwan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With advances in molecular biologic and genomic technology, detailed molecular mechanisms for development of castration-resistant prostate cancer (CRPC) have surfaced. Metastatic prostate cancer (PCa) no longer represents an end stage, with many emerging therapeutic agents approved as effective in prolonging survival of patients from either pre- or post-docetaxel stage. Given tumor heterogeneity in patients, a one-size-fits-all theory for curative therapy remains questionable. With the support of evidence from continuing clinical trials, each treatment modality has gradually been found suitable for selective best-fit patients: e.g., new androgen synthesis inhibitor arbiraterone, androgen receptor signaling inhibitor enzalutamide, sipuleucel-T immunotherapy, new taxane carbazitaxel, calcium-mimetic radium-223 radiopharmaceutical agent. Moreover, several emerging immunomodulating agents and circulating tumor cell enumeration and analysis showed promise in animal or early phase clinical trials. While the era of personalized therapy for CRPC patients is still in infancy, optimal therapeutic agents and their sequencing loom not far in the future.

Indexed as

Castration-resistant prostate cancerPersonalized cancer therapyProstate cancer

Identifiers

PMID25520915
PMCPMC4264971

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.